CureVac N.V. (5CV.F)

8.2 €

-0.51 (-5.86%)
Symbol 5CV.F
Price 8.2 €
Beta 2.886
Volume Avg. 0.01M
Market Cap 1.836B
Shares () -
52 Week Range 5.3-18.432
1y Target Est -
DCF Unlevered 5CV.F DCF ->
DCF Levered 5CV.F LDCF ->
ROE -18.71% Sell
ROA -13.42% Sell
Operating Margin -
Debt / Equity 45.68% Neutral
P/E -6.46 Strong Sell
P/B 2.42 Strong Buy


Consensus EPS

Upgrades & Downgrades

Dr. Alexander Zehnder M.B.A., M.D.

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.